Log in

Relevant bibliographies by topics / 025.063 337 091 638 4

Contents

Journal articles

Academic literature on the topic '025.063 337 091 638 4'

Author: Grafiati

Published: 4 June 2021

Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '025.063 337 091 638 4.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "025.063 337 091 638 4"

1

Kepert, Cameron J., Peter C. Junk, Brian W. Skelton, and Allan H. White. "Structural Systematics of Rare Earth Complexes. XX (Maximally) Hydrated Rare Earth Sulfates and the Double Sulfates (NH4)Ln(SO4)2.4H2O (Ln = La, Tb)." Australian Journal of Chemistry 52, no. 6 (1999): 601. http://dx.doi.org/10.1071/ch98050.

Full text

Abstract:

Room-temperature single-crystal X-ray studies carried out on trivalent rare earth sulfate hydrates, Ln2(SO4)3.xH2O, crystallized at local ambience suggest the following arrays to be prevalent. For Ln = La, the nonahydrate is found, hexagonal P 63/m, with conventional R on |F| 0·023 for No 1159 ‘observed’ (I >3σ(I)) diffractometer reflections (redetermination). Although for Ln = Ce a similar structure has been previously recorded, we have obtained that adduct as the monoclinic C 2/c, Z = 4, octahydrate, a phase also found for Ln = Lu and diverse representative intermediate lanthanoids: a ≈ 1

APA, Harvard, Vancouver, ISO, and other styles

2

Zhang, Lingyun, Xiujuan Qu, Yuee Teng, et al. "Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)." Journal of Clinical Oncology 35, no. 31 (2017): 3558–65. http://dx.doi.org/10.1200/jco.2017.72.2538.

Full text

Abstract:

Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC). Patients and Methods In a randomized, double-blind, active-controlled, phase III trial, chemotherapy-naive patients with cancer who were scheduled to receive HEC that contained cisplatin or cyclophosphamide-doxorubicin/epirubincin ≥ 50 mg/m2 regimens were randomly assigned to a THD group (100 mg twice daily on days 1 to 5) or placebo group, both with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8

APA, Harvard, Vancouver, ISO, and other styles

3

Park, Junghyun, and Marc Rodger. "Retrospective Cohort of Unprovoked Venous Thromboembolism Patients: What Proportion Have Potent Thrombophilias Necessitating Indefinite Anticoagulants?" Blood 126, no. 23 (2015): 2318. http://dx.doi.org/10.1182/blood.v126.23.2318.2318.

Full text

Abstract:

Introduction Thrombophilia testing in unprovoked venous thromboembolism patients (VTE) is controversial. Common thrombophilias such as Factor V Leiden or prothrombin gene variant appear to not importantly increase the risk of VTE recurrence, and thus are not considered in anticoagulation management decisions. However, patients with potent thrombophilias such as antiphospholipid antibodies (APLA), antithrombin deficiency, protein C and S deficiency, and homozygous genetic thrombophilias or combined defects are at higher risk of recurrence and it is recommended that they receive long-term antico

APA, Harvard, Vancouver, ISO, and other styles

4

Koemel, Nicholas A., Christina M. Sciarrillo, Katherine B. Bode, et al. "Postprandial Metabolism and Vascular Function: Impact of Aging and Physical Activity Level." International Journal of Sport Nutrition and Exercise Metabolism 30, no. 6 (2020): 412–19. http://dx.doi.org/10.1123/ijsnem.2020-0063.

Full text

Abstract:

The consumption of a high-fat meal can induce postprandial lipemia and endothelial dysfunction. The authors assessed the impact of age and physical activity on metabolic and vascular outcomes following meal consumption in healthy adults. The authors recruited four groups: younger active (age 22.1 ± 1.4 years; n = 9), younger inactive (age 22.6 ± 3.7 years; n = 8), older active (age 68.4 ± 7.7 years; n = 8), and older inactive (age 67.7 ± 7.2 years; n = 7). The metabolic outcomes were measured at the baseline and hourly for 6 hr post high-fat meal consumption (12 kcal/kg; 63% fat). Flow-mediate

APA, Harvard, Vancouver, ISO, and other styles

5

Heikura, Ida A., Louise M. Burke, Dan Bergland, Arja L. T. Uusitalo, Antti A. Mero, and Trent Stellingwerff. "Impact of Energy Availability, Health, and Sex on Hemoglobin-Mass Responses Following Live-High–Train-High Altitude Training in Elite Female and Male Distance Athletes." International Journal of Sports Physiology and Performance 13, no. 8 (2018): 1090–96. http://dx.doi.org/10.1123/ijspp.2017-0547.

Full text

Abstract:

Purpose: The authors investigated the effects of sex, energy availability (EA), and health status on the change in hemoglobin mass (ΔHbmass) in elite endurance athletes over ∼3–4 wk of live-high–train-high altitude training in Flagstaff, AZ (2135 m; n = 27 women; n = 21 men; 27% 2016 Olympians). Methods: Precamp and postcamp Hbmass (optimized carbon monoxide rebreathing method) and iron status were measured, EA was estimated via food and training logs, and a Low Energy Availability in Females Questionnaire (LEAFQ) and a general injury/illness questionnaire were completed. Hypoxic exposure (h)

APA, Harvard, Vancouver, ISO, and other styles

6

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text

Abstract:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

APA, Harvard, Vancouver, ISO, and other styles

7

D’cruz, D., G. Eriksson, Y. Green, et al. "POS0696 SAFETY AND EFFICACY OF BELIMUMAB IN OLDER ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF AN INTEGRATED ANALYSIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 596.1–596. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2217.

Full text

Abstract:

Background:Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterised by persistent B-cell activation. Belimumab (BEL), a monoclonal antibody that inhibits B-lymphocyte stimulator, is approved in patients aged ≥5 years with active autoantibody-positive SLE; however, safety and efficacy data of BEL in older adults are limited.Objectives:Assess the safety and efficacy of BEL in older adults with SLE.Methods:A meta-analysis (GSK study 116559) was performed on the subpopulation of patients aged ≥65 years and compared with the overall population pooled from six controlled, re

APA, Harvard, Vancouver, ISO, and other styles

8

Walschot, Luc H. B., Robert J. F. Laheij, and André L. M. Verbeek. "Outcome after Endovascular Abdominal Aortic Aneurysm Repair: A Meta-Analysis." Journal of Endovascular Therapy 9, no. 1 (2002): 82–89. http://dx.doi.org/10.1177/152660280200900114.

Full text

Abstract:

Purpose: To determine the frequencies of complications and risk factors for complications following endovascular abdominal aortic aneurysm (AAA) repair (EVAR). Methods: Thirty-nine articles published between October 1995 and October 1999 in English, German, French, or Dutch were identified in electronic databases. All articles reported perioperative (30-day) complications on 2387 patients, while postoperative complications (>30 days) were reported on 1645 patients in 30 of 39 studies. Data were pooled and subjected to multivariable logistic regression analysis to identify risk factors for d

APA, Harvard, Vancouver, ISO, and other styles

9

Ganhão, S., S. Garcia, B. M. Fernandes, et al. "SAT0416 ENTHESITIS AND CLINICAL RESPONSE IN PSORIATIC ARTHRITIS: REAL-LIFE DATA." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1161.1–1161. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4543.

Full text

Abstract:

Background:Psoriatic arthritis (PsA) is an inflammatory arthritis that is characterized by a broad spectrum of clinical conditions, including axial skeletal involvement, enthesitis, dactylitis, uveitis and arthritis. Among those, enthesitis, the inflammation of the junction where the tendon, ligament or joint capsule inserts into the bone, is assigned to be the hallmark, affecting 35–50% of patients. Several clinical methods have been developed to measure it, including The Maastricht AS Enthesitis Score (MASES) index, which tests 13 entheses and the Spondyloarthritis Research Consortium of Can

APA, Harvard, Vancouver, ISO, and other styles

10

Ritchlin, C. T., P. Rahman, P. Helliwell, et al. "AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1300–1301. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1334.

Full text

Abstract:

Background:DISCOVER 1 & 2, two double-blind, phase-3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs placebo (PBO) in signs and symptoms of PsA, with good tolerability, at week (w) 24 during the PBO-controlled period.1,2 Beyond w24, all patients (pts) switched to GUS. Continued treatment maintained efficacy through w52.3,4Objectives:To describe pooled safety results from the DISCOVER 1 & 2 trials through 1-year of GUS treatment.Methods:Adults with active PsA (DISCOVER 1: ≥3 tender/swollen joints and C-Reactive

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!